Jula Inrig

Nephrologist, researcher, mom.

[Jula Inrig @InrigJula]

What Hope Means in FSGS https://t.co/kvvJ5Z0pHU

[Jula Inrig @InrigJula]

Check out my latest article: When Clinical Guidelines Evolve, Patient Care Improves https://t.co/FcDJ6svfIw via @LinkedIn

[Jula Inrig @InrigJula]

Happy World Kidney Day https://t.co/fTCpnFSqdC

[Travere Therapeutics @TravereRare]

Today we announced that we plan to submit a supplemental New Drug Application (sNDA) to the U.S. FDA for sparsentan in focal segmental glomerulosclerosis (#FSGS). Press release: https://t.co/xHtnjYbu32 #InRareForLife

[Travere Therapeutics @TravereRare]

We’d like to extend a huge thank you to @ASNKidney and to everyone who joined us at #ASN24 #KidneyWk. It was a pleasure coming together and sharing our clinical data and research in #IgAN and #FSGS. Thank you to all those who contributed to another thought-provoking and inspiring meeting on advances in #RareKidneyDisease (RKD).

[Jula Inrig @InrigJula]

@DanTheKidneyMan @KidneyMed @ASNKidney360 @MikeAllonK360 @MRrenaldoc Some great people shown here!

[Travere Therapeutics @TravereRare]

“When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced,” writes Jula Inrig, M.D., chief medical officer at Travere. Check out her recent article about #RareKidneyDisease and #IgAnephropathy in Fierce Biotech. #InRareForLife https://t.co/5zE0g5VOL4

[Travere Therapeutics @TravereRare]

Today we announced that we’ll present 11 abstracts at the upcoming @ASNKidney #ASN24 #KidneyWk in San Diego, CA, later this month on our work in #RareKidneyDisease. #InRareForLife https://t.co/2iqBcPnOUs

[Jula Inrig @InrigJula]

@OhioStateNeph @OSUWexMed @BradRovin Congratulations, well deserved!

[CheckRare @CheckRare]

Jula Inrig, MD, Chief Medical Officer at Travere Therapeutics, discusses a clinical trial that tested sparsentan for treatment of IgA nephropathy, compared to traditional RAS inhibitors. #CheckRare #RareDisease #IgANephropathy
https://t.co/asjG3numni

[Hans-Joachim Anders @hjanders_hans]

JCI Insight - Sparsentan improves glomerular hemodynamics, cell functions and tissue repair in a mouse model of FSGS https://t.co/P9uiH0Njx7

[Jula Inrig @InrigJula]

For all the years I’ve treated people living with IgAN, today marks a new chapter and brings me profound hope for this patient community that has waited for so long. #InRareForLife

[Travere Therapeutics @TravereRare]

We are excited to announce that our medicine for the treatment of #IgAnephropathy was granted full approval by the FDA. Today’s approval marks an important milestone in transforming treatment for people living with #RareKidneyDisease. Press release: https://t.co/xzbVWDdpop

[Travere Therapeutics @TravereRare]

We are excited to announce that our medicine for the treatment of #IgAnephropathy was granted full approval by the FDA. Today’s approval marks an important milestone in transforming treatment for people living with #RareKidneyDisease. Press release: https://t.co/xzbVWDdpop

[Jula Inrig @InrigJula]

@julierenal Life is so much better with a lot of laughter…and champagne! Let’s keep the tradition going for decades to come :)

[Travere Therapeutics @TravereRare]

“There’s always a little love for the glomerulus,” said Jula Inrig, M.D., CMO of Travere Therapeutics during a podcast with the @ISGDtweets. Jula talks about her career, Kidney Health Initiative, endothelin physiology, and clinical trials of sparsentan in IgAN and FSGS

[HCPLive @HCPLiveNews]

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings.

https://t.co/eH84J89Jm9
#NKFClinicals #SCM24 #LateBreakers

[American Physiological Society @APSPhysiology]

#APSselect mouse study from @AJPRenal finds the nephropathy drug sparsentan improves changes in the kidney associated with inflammatory genes and pathways: https://t.co/TYnWSg5tE5 CC: @AJPRenalEIC

[Travere Therapeutics @TravereRare]

We are delighted to share abstracts at @nkf #SCM24 on our research in #RKD, including analyses comparing the effect of sparsentan as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus RASi in real-world use and in clinical trials in patients with #IgAN.

[World Congress of Nephrology @ISNWCN]

"SPARSENTAN as First-line Treatment of Incident Patients With IgAN: Preliminary Findings from the SPARTAN Trial" by @toomuchaltitude, et al, was presented at WCN'24. Their work was transformed into a visual abstract by #ISNWCN Social Media Team member @Ironken6

[International Society of Glomerular Disease @ISGDtweets]

In our latest GN in Ten episode, @koyaljainMD and @kdjhaveri chat with @InrigJula about endothelin, sparsentan, the art & science of clinical trial design, clinical research careers outside academia, and how we got to this "golden era" of neph trials.
https://t.co/kPb7uCocRz